Piramal Pharma narrows Q1 loss as consumer-health e-commerce rises 40%
Piramal Pharma’s Q1 FY27 revenue rose 17.4% to ₹2,269.9 crore and EBITDA jumped 82.9%. In Consumer Healthcare, Power Brands grew 23%, while e-commerce revenue rose 40% to contribute 28% of sales. The company also launched women’s intimate-care brand i-choose.
Piramal Pharma narrowed its Q1 FY27 loss as revenue rose 17.4% and EBITDA nearly doubled. Consumer Healthcare growth was led by Power Brands, e-commerce, distribution expansion and premiumisation; the company launched i-choose for women’s intimate care.
Why this matters
No related recent signals were provided. Q1 FY27 results indicate Piramal Pharma is pairing improved profitability with faster digital growth in Consumer Healthcare.
Retail-company signals are accelerating, up 410200% quarter over quarter.